BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV

The 59th American Society of Hematology (ASH) Annual Meeting is just around the corner. More than 250 pharmaceutical companies will be participating in the meeting which will be held between December 9 and December 12, 2017, at Atlanta, Georgia.

Here’s another list of companies that will be presenting new data or updated analyses from their hematology clinical trials.

It’s been a banner year for Blueprint Medicines Corp. (BPMC), whose stock price has climbed a whopping 148% year-to-date.

The Company is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases.

BLU-285 and BLU-554 are the two lead drug candidates of the Company, both of which are under phase I clinical trials.

BLU-285 is being explored in the indications of advanced gastrointestinal stromal tumors and advanced systemic mastocytosis. BLU-554 is in development for hepatocellular carcinoma.

At the American Society of Hematology (ASH) Annual Meeting, on December 10, 2017, the Company will be presenting updated data from its ongoing phase I clinical trial of BLU-285 for the treatment of advanced systemic mastocytosis.

Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. (Source: NIH).

BPMC closed Monday’s (Dec.4) trading at $69.71, down 4.27%.

Shares of Fate Therapeutics Inc. (FATE) are up an impressive 66% year-to-date.

The Company is focused on developing programmed cellular immunotherapies for cancer and immune disorders.

At the ASH Meeting on December 11, 2017, the Company will be presenting Day 100 efficacy data from its phase I study of ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing matched unrelated donor hematopoietic cell transplantation (HCT), dubbed PROTECT.

The phase II stage of the PROTECT study was initiated as recently as September based on recommendations of an independent data monitoring committee. All subjects met the Day 28 safety objectives of neutrophil engraftment and survival, and reached Day 28 without any events of graft failure or serious adverse events related to ProTmune.

FATE closed Monday’s (Dec.4) trading at $4.17, down 5.01%.

Shares of Syros Pharmaceuticals Inc. (SYRS) are down 40% from their 52-week high of $24.38 recorded in August.

The Company is pioneering a new area of medicine focused on…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *